个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wang Wenxian[1] * ; Wang Qian[2] * ; Xu Chunwei[3,4] * ; Li Ziming[5] ; Song Zhengbo[1] ; Zhang Yongchang[6] ; Cai Xiuyu[7] ; Zhang Shirong[8] ; Lian Bin[9] ; Li Wen[10] ; Liu Anwen[11] ; Zhan Ping[4] ; Liu Hongbing[4] ; Lv Tangfeng[4] ; Miao Liyun[12] ; Min Lingfeng[13] ; Chen Yu[14] ; Yuan Jingping[15] ; Wang Feng[16] ; Jiang Zhansheng[17] ; Lin Gen[14] ; Pu Xingxiang[18] ; Rao Chuangzhou[19] ; Lv Dongqing[20] ; Yu Zongyang[21] ; Li Xiaoyan[22] ; Tang Chuanhao[23] ; Zhou Chengzhi[24] ; Xie Congying[25] ; Zhang Junping[26] ; Guo Hui[27] ; Chu Qian[28] ; Meng Rui[29] ; Wu Jingxun[30] ; Zhang Rui[31] ; Wang Liping[32] ; Zhu Youcai[33] ; Hu Xiao[34] ; Xie Yanru[35] ; Lin Xinqing[24] ; Cai Jing[11] ; Lan Fen[10] ; Feng Huijing[26] ; Wang Lin[36] ; Yao Wang[37] ; Shi Xuefei[38] ; Huang Jianhui[35] ; Chen Huafei[33] ; Zhang Yinbin[39] ; Sun Pingli[40] ; Wan Bing[41] ; Pang Fei[42] ; Xu Zanmei[42] ; Wang Kai[42] ; Xia Yuanli[43] ; Ye Mingxiang[4] ; Wang Dong[4] ; Wei Qing[1] ; Feng Shuitu[44] ; Zhou Jianya[45] ; Zhang Jiexia[24] ; Lv Donglai[46] ; Gao Wenbin[47] ; Kang Jing[48] ; Yu Genhua[49] ; Liang Xianbin[50] ; Yu Chengtao[51] ; Shi Lin[52] ; Yang Nong[6] ; Wu Lin[18] ; Hong Zhuan[53] ; Hong Wei[1] ; Fang Meiyu[1] ; Zhang Yiping[1] ; Lu Yuanzhi[54] ; Wang Guansong[55] ; Ma Shenglin[56] ; Si Lu[9,*1] ; Fang Wenfeng[57,*2] ; Song Yong[4,*3] ;
机构： [1]Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China. [2]Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China. [3]Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China. [4]Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China. [5]Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China. [6]Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. [7]Department of VIP Inpatient, Sun Yet-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. [8]Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China. [9]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China. [10]Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China. [11]Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, China. [12]Department of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. [13]Department of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou, China. [14]Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China. [15]Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, China. [16]Department of Internal Medicine, Cancer Center of PLA, Qinhuai Medical Area, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China. [17]Derpartment of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. [18]Department of Medical Oncology, Lung Cancer, and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. [19]Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, China. [20]Department of Pulmonary Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou, China. [21]Department of Respiratory Medicine, The 900th Hospital of the Joint Logistics Team (The Former Fuzhou General Hospital), Fujian Medical University, Fuzhou, China. [22]Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. [23]Department of Medical Oncology, Peking University International Hospital, Beijing, China. [24]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University (The First Affiliated Hospital of Guangzhou Medical University), Guangzhou, China. [25]Department of Radiation Oncology, First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China. [26]Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, China. [27]Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. [28]Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [29]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [30]Department of Medical Oncology, The First Affiliated Hospital of Medicine, Xiamen University, Xiamen, China. [31]Department of Medical Oncology, Cancer Hospital of China Medical University, Shenyang, China. [32]Department of Oncology, Baotou Cancer Hospital, Baotou, China. [33]Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing, China. [34]Zhejiang Key Laboratory of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. [35]Department of Oncology, Lishui Municipal Central Hospital, Lishui, China. [36]Department of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan, China. [37]Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. [38]Department of Respiratory Medicine, Huzhou Hospital, Zhejiang University School of Medicine, Huzhou, China. [39]Department of Oncology, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China. [40]Department of Pathology, The Second Hospital of Jilin University, Changchun, China. [41]Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China. [42]Department of Medical, Shanghai OrigiMed Co. Ltd, Shanghai, China. [43]Department of Medical Affairs, AstraZeneca China, Shanghai, China. [44]Department of Oncology, Xiamen Haicang Hospital, Xiamen, China. [45]Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. [46]Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei, China. [47]Department of Oncology, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China. [48]Guangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou, China. [49]Department of Radiation Oncology, Zhebei Mingzhou Hospital, Huzhou, China. [50]Department of Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China. [51]Collaborative Innovation Center of Jiangsu Province of Cancer Prevention and Treatment of Chinese Medicine, Nanjing, China. [52]Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. [53]Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China. [54]Department of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou, China. [55]Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing, China. [56]Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou, China. [57]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
出处：
DOI： 10.1111/1759-7714.14693
ISSN：

关键词： checkpoint inhibitor pneumonitis Chinese experts consensus immune checkpoint inhibitor-related adverse effects

摘要：
Immune checkpoint inhibitors (ICIs) have successfully treated a number of different types of cancer, which is of great significance for cancer treatment. With the widespread use of ICIs in clinical practice, the increasing checkpoint inhibitor pneumonia (CIP) will be a challenge to clinicians. To guide the diagnosis and treatment of CIP, we conducted in-depth discussions based on the latest evidence, forming a consensus among Chinese experts on the multidisciplinary management of CIP.© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学 3 区 呼吸系统
最新[2025]版：
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 呼吸系统
JCR分区：
出版当年[2020]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY
最新[2023]版：
Q2 RESPIRATORY SYSTEM Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者机构： [1]Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou, China.
共同第一作者：
通讯作者：
通讯机构： [4]Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China. [9]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China. [57]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. [*1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing 100142, China [*2]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, China [*3]Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210002, China
推荐引用方式(GB/T 7714)：
Wang Wenxian,Wang Qian,Xu Chunwei,et al.Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor[J].THORACIC CANCER.2022,13(23):3420-3430.doi:10.1111/1759-7714.14693.
APA：
Wang Wenxian,Wang Qian,Xu Chunwei,Li Ziming,Song Zhengbo...&Song Yong.(2022).Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.THORACIC CANCER,13,(23)
MLA：
Wang Wenxian,et al."Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor".THORACIC CANCER 13..23(2022):3420-3430

相关文献

[1]Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report [2]显微血管减压术围手术期电生理评估中国专家共识 [3]溃疡性结肠炎中医诊疗专家共识（2023） [4]中国结直肠癌骨转移多学科综合治疗专家共识（2020版） [5]经肛吻合器治疗脱垂性痔中国专家共识 [6]即时检测（POCT）临床结果报告与发布中国专家共识 [7]中医临床名词术语 第2部分：外科学 [8]中医临床名词术语 第6部分：妇科学 [9]四逆汤对大鼠肠缺血再灌注后肠粘膜细胞凋亡的影响及神经酰胺机制 [10]利多卡因胶带皮肤镇痛作用探讨

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号